Drug Trial Radar · NCT00348348
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,161
Actual
Start
Jun 2006
Primary completion
Jul 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.
Conditions
- Acute Bacterial Conjunctivitis
Interventions
BesifloxacinDrug
Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
Moxifloxacin solutionDrug
Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical ResolutionTime frame: Day 5(+/- 1 day)
- Microbial EradicationTime frame: Day 5 (+/- 1 day)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.